Colorectal Cancer — Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers
Citation(s)
Phase I/Ib Study With the Combination of RMC-4630 (SHP2 Inhibitor) and LY3214996 (ERK Inhibitor) in Metastatic KRAS Mutant CRC, PDAC and NSCLC